Mindfulness-based stress reduction in Parkinson's disease: a systematic review

G McLean, M Lawrence, R Simpson, S W Mercer, G McLean, M Lawrence, R Simpson, S W Mercer

Abstract

Background: Mindfulness based stress reduction (MBSR) is increasingly being used to improve outcomes such as stress and depression in a range of long-term conditions (LTCs). While systematic reviews on MBSR have taken place for a number of conditions there remains limited information on its impact on individuals with Parkinson's disease (PD).

Methods: Medline, Central, Embase, Amed, CINAHAL were searched in March 2016. These databases were searched using a combination of MeSH subject headings where available and keywords in the title and abstracts. We also searched the reference lists of related reviews. Study quality was assessed based on questions from the Cochrane Collaboration risk of bias tool.

Results: Two interventions and three papers with a total of 66 participants were included. The interventions were undertaken in Belgium (n = 27) and the USA (n = 39). One study reported significantly increased grey matter density (GMD) in the brains of the MBSR group compared to the usual care group. Significant improvements were reported in one study for a number of outcomes including PD outcomes, depression, mindfulness, and quality of life indicators. Only one intervention was of reasonable quality and both interventions failed to control for potential confounders in the analysis. Adverse events and reasons for drop-outs were not reported. There was also no reporting on the costs/benefits of the intervention or how they affected health service utilisation.

Conclusion: This systematic review found limited and inconclusive evidence of the effectiveness of MBSR for PD patients. Both of the included interventions claimed positive effects for PD patients but significant outcomes were often contradicted by other results. Further trials with larger sample sizes, control groups and longer follow-ups are needed before the evidence for MBSR in PD can be conclusively judged.

Keywords: Brain; Depression; Mindfulness; Parkinson’s Disease; Quality of Life; Systematic Review.

Figures

Fig. 1
Fig. 1
Flowchart for PD review

References

    1. Jankovic J. Parkinson’s disease: clinical features and diagnosis. Neurol Neurosurg Psychiatry. 2008;79:368–376. doi: 10.1136/jnnp.2007.131045.
    1. Bonnet AM, Jutras MF, Czernecki V, Corvol JC, Vidailhet M. Nonmotor symptoms in Parkinsons disease in 2012: relevant clinical aspects. Parkinsons Dis. 2012;15:198316.
    1. Koerts J, Leenders KL, Koning M, Bouma A, van Beilen M. The assessment of depression in Parkinson’s disease. Eur J Neurol. 2008;15:487–492. doi: 10.1111/j.1468-1331.2008.02101.x.
    1. Simpson J, Lekwuwa G, Crawford T. Predictors of quality of life in people with Parkinson’s disease: evidence for both domain specific and general relationships. Disabil Rehabil. 2014;36(23):1964–1970. doi: 10.3109/09638288.2014.883442.
    1. Hemmerle AM, Herman JP, Seroogy KB. Stress, depression and Parkinson’s disease. Exp Neurol. 2012;233(1):79–86. doi: 10.1016/j.expneurol.2011.09.035.
    1. Oehlberg K, Barg FK, Brown GK, Taraborelli D, Stern MB, Weintraub D. Attitudes regarding the etiology and treatment of depression in Parkinson’s disease: a qualitative study. J Geriatr Psychiatry Neurol. 2008;21:123–132. doi: 10.1177/0891988708316862.
    1. Wang Y, Xie C-L, Wang W-W, et al. Epidemiology of complementary and alternative medicine use in patients with Parkinson’s disease. J Clin Neurosci. 2013;20(8):1062–1067. doi: 10.1016/j.jocn.2012.10.022.
    1. Kabat-Zinn J, Lipworth L, Burney R, Sellers W. Four year follow-up of a meditation-based program for the self regulation of chronic pain: treatment outcomes and compliance. Clin J Pain. 1986;2(3):159–173. doi: 10.1097/00002508-198602030-00004.
    1. Kabat-Zinn J, Lipworth L, Burney R. The clinical use of mindfulness meditation for the self-regulation of chronic pain. J Behav Med. 1985;8:163–190. doi: 10.1007/BF00845519.
    1. Gotink RA, Chu P, Busschbach JJ, Benson H, Fricchione GL, Hunink MG. Standardised mindfulness-based interventions in healthcare: an overview of systematic reviews and meta-analyses of RCTs. PLoS One. 2015;10(4):e0124344. doi: 10.1371/journal.pone.0124344.
    1. Piet J, Wurtzen H, Zachariae R. The effect of mindfulness-based therapy on symptoms of anxiety and depression in adult cancer patients and survivors: a systematic review and meta-analysis. J Consult Clin Psychol. 2012;80:1007–1020. doi: 10.1037/a0028329.
    1. Smith JE, Richardson J, Hoffman C, Pilkington K. Mindfulness-based stress reduction as supportive therapy in cancer care: systematic review. J Adv Nurs. 2005;52:315–327. doi: 10.1111/j.1365-2648.2005.03592.x.
    1. Veehof MM, Oskam MJ, Schreurs KMG, Bohlmeijer ET. Acceptance-based interventions for the treatment of chronic pain: a systematic review and meta-analysis. Pain. 2011;152:533–542. doi: 10.1016/j.pain.2010.11.002.
    1. Kozasa EH, Tanaka LH, Monson C, Little S, Leao FC, et al. The effects of meditation-based interventions on the treatment of fibromyalgia. Curr Pain Headache 2012, Rep 16: 383–387.
    1. Abbott RA, Whear R, Rodgers LR, Bethel A, Thompson Coon J, et al. Effectiveness of mindfulness-based stress reduction and mindfulness based cognitive therapy in vascular disease: a systematic review and meta-analysis of randomised controlled trials. J Psychosom Res. 2014;76:341–351. doi: 10.1016/j.jpsychores.2014.02.012.
    1. Lawrence M, Booth J, Mercer S, Crawford E. A systematic review of the benefits of mindfulness-based interventions following transient ischaemic attack and stroke. Int J Stroke. 2013;8:465–474. doi: 10.1111/ijs.12135.
    1. Simpson R, Booth J, Lawrence M, Byrne S, Mair F, Mercer S. Mindfulness based interventions in multiple sclerosis--a systematic review. BMC Neurol. 2014;14:15. doi: 10.1186/1471-2377-14-15.
    1. McLean G, Mercer S, Lawrence M. Mindfulness based stress reduction in Parkinson’s disease. PROSPERO 2016: CRD42016035304.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.
    1. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995 Nov–Dec;123(3):A12–3.
    1. Moher D, Pham B, Lawson ML, Klassen TP. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess. 2003;7:1–90. doi: 10.3310/hta7410.
    1. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group Cochrane statistical methods group: the Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.
    1. Cash TV, Ekouevi VS, Kilbourn C, Lageman SK. Pilot study of a mindfulness-based group intervention for individuals with Parkinson’s disease and their caregivers. Mindfulness. 2016;7:361–371. doi: 10.1007/s12671-015-0452-1.
    1. Pickut BA, Van Hecke W, Kerckhofs E, et al. Mindfulness based intervention in Parkinson's disease leads to structural brain changes on MRI: a randomized controlled longitudinal trial. Clin Neurol Neurosurg. 2013;115(12):2419–2425. doi: 10.1016/j.clineuro.2013.10.002.
    1. Pickut B, Vanneste S, Hirsch MA, Van Hecke W, Kerckhofs E, Mariën P, Parizel PM, Crosiers D, Cras P. Mindfulness training among individuals with Parkinson's disease: neurobehavioral effects. Park Dis. 2015;2015:816404.
    1. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the unified Parkinson’s disease Rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170. doi: 10.1002/mds.22340.
    1. Chaudhuri K, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, et al. The non declaration of non motor symptoms of Parkinson’s disease to health care professionals: an international study using the non motor symptoms questionnaire. Mov Disord. 2010;25:704–709. doi: 10.1002/mds.22868.
    1. De la Fuente-Fernandez R, Schulzer M, Stoessl AJ. The placebo effect in neurological disorders. Lancet Neurol. 2002;1:85–91. doi: 10.1016/S1474-4422(02)00038-8.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Levin BE, Llabre MM, Weiner WJ. Parkinson’s disease and depression: psychometric properties of the Beck depression Inventory. J Neurol Neurosurg Psychiatry. 1988;51(11):1401–1404. doi: 10.1136/jnnp.51.11.1401.
    1. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–1097. doi: 10.1001/archinte.166.10.1092.
    1. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s disease questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing. 1997;26(5):353–357. doi: 10.1093/ageing/26.5.353.
    1. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134–139. doi: 10.1176/jnp.4.2.134.
    1. Baer R, Smith G, Hopkin J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment. 2006;13(1):27–45. doi: 10.1177/1073191105283504.
    1. Fitzpatrick L, Simpson J, Smith A, “A qualitative analysis of mindfulness-based cognitive therapy (MBCT) in Parkinson's disease,” Psychol Psychother 2010, vol. 83, part 2, pp. 179–192.
    1. Lustyk M, Chawla N, Nolan R, Marlatt G. Mindfulness meditation research: issues of participant screening, safety procedures, and researcher training. Adv Mind Body Med. 2009;24:20–30.
    1. Advocat J, Enticott J, Vandenberg B, Hassed C, Hester J, Russell G. The effects of a mindfulness-based lifestyle program for adults with Parkinson’s disease: a mixed methods, wait list controlled randomised control study. BMC Neurol. 2016;16:166. doi: 10.1186/s12883-016-0685-1.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner